Altimmune Statistics
Altimmune (0A4C) Stock Statistics & Valuation Metrics
Total Valuation
Altimmune has a market cap or net worth of $375.42M. The enterprise value is $273.45M.
- Market Cap
- $375.42M
- Enterprise Value
- $273.45M
Share Statistics
Altimmune has 194,517,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 194,517,700
- Owned by Insiders
- 0.42%
- Owned by Institutions
- 27.54%
Financial Efficiency
Altimmune’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -35.36%.
- Return on Equity (ROE)
- -0.39
- Return on Assets (ROA)
- -0.31
- Return on Invested Capital (ROIC)
- -35.36%
- Return on Capital Employed (ROCE)
- -0.36
- Revenue Per Employee
- 719.298
- Profits Per Employee
- -1.55M
- Employee Count
- 57
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Altimmune is -2.31. Altimmune’s PEG ratio is -0.05.
- PE Ratio
- -2.31
- PS Ratio
- 12456.61
- PB Ratio
- 0.77
- Price to FCF
- -4.23
- Price to Operating Cash Flow
- -4.47
- PEG Ratio
- -0.05
Income Statement
In the last 12 months, Altimmune had revenue of 41.00K and earned -88.09M in profits. Earnings per share was -1.00.
- Revenue
- 41.00K
- Gross Profit
- 41.00K
- Operating Income
- -94.49M
- Pretax Income
- -88.77M
- Net Income
- -88.09M
- EBITDA
- -87.03M
- Earnings Per Share (EPS)
- -1.00
Cash Flow
In the last 12 months, operating cash flow was -76.51M and capital expenditures -54,000, giving a free cash flow of -76.56M billion.
- Operating Cash Flow
- -76.51M
- Free Cash Flow
- -76.56M
- Free Cash Flow per Share
- -0.37
Dividends & Yields
Altimmune pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -24.02%
- Earnings Yield
- -31.02%
Stock Price Statistics
- Beta
- 1.04
- 52-Week Price Change
- -32.02%
- 50-Day Moving Average
- 2.89
- 200-Day Moving Average
- 3.95
- Relative Strength Index (RSI)
- 0.12
- Average Volume (3m)
- ―
Important Dates
Altimmune upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Altimmune as a current ratio of 18.55, with Debt / Equity ratio of 15.87%
- Current Ratio
- 18.55
- Quick Ratio
- 18.55
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- 0.09
- Interest Coverage Ratio
- -57.76
Taxes
In the past 12 months, Altimmune has paid -681.00K in taxes.
- Income Tax
- -681.00K
- Effective Tax Rate
- 0.01
Enterprise Valuation
Altimmune EV to EBITDA ratio is -3.24, with an EV/FCF ratio of -4.24.
- EV to Sales
- 12494.51
- EV to EBITDA
- -3.24
- EV to Free Cash Flow
- -4.24
- EV to Operating Cash Flow
- -4.25
Balance Sheet
Altimmune has $326.32M in cash and marketable securities with $35.75M in debt, giving a net cash position of $290.58M billion.
- Cash & Marketable Securities
- $326.32M
- Total Debt
- $35.75M
- Net Cash
- $290.58M
- Net Cash Per Share
- $1.49
- Tangible Book Value Per Share
- $2.56
Margins
Gross margin is -238196.15%, with operating margin of -442580.77%, and net profit margin of -401361.54%.
- Gross Margin
- -238196.15%
- Operating Margin
- -442580.77%
- Pretax Margin
- -401361.54%
- Net Profit Margin
- -401361.54%
- EBITDA Margin
- -385076.92%
- EBIT Margin
- -385353.85%
Analyst Forecast
The average price target for Altimmune is $18.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $18.50
- Price Target Upside
- 540.36% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 30.00%
- EPS Growth Forecast
- 31.68%
Scores
- Smart Score
- 7
- AI Score
- ―
